Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.

The company is developing MGL-3196, the first orally administered, small-molecule, liver-directed, truly β-selective thyroid hormone receptor (THR) agonist. In preclinical and Phase 1 studies, MGL-3196 has demonstrated a broad array of therapeutically beneficial effects, improving components of both metabolic syndrome, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation.

Based on this initial evidence of broad activity and a favorable safety profile, Madrigal has initiated Phase 2 clinical trials of MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH).